INTRODUCTION
The pathophysiology of hepatic encephalopathy is still not well understood despite many investigations that have been carried out during the last 50 years. Neurological manifestations are considered to result from a derangement of multiple neurotransmitter systems. Accumulation of several neurotoxic substances have been reported and it is likely that many of them contribute to the pathogenesis of HE. Manganese has been suggested recently as another candidate substance. There is increasing evidence to suggest that manganese deposition occurs in the brain (and more specifically in the basal ganglia) of patients with chronic liver disease and also in patients with spontaneous or surgicallyinduced portacaval shunt (PCS).
EVIDENCE FOR BRAIN MANGANESE OVERLOAD IN CHRONIC LIVER DISEASES
Pallidal signal hyperintensity on magnetic resonance imaging (MRI) has been observed in a majority of cirrhotic patients (Figure 1 ; Krieger et al., 1996; Pujol et al., 1993; Spahr et al., 1996) . Such images could theoretically be caused by lipid deposition, calcification, melanin, methemoglobin or manganese. Recent autopsy studies in cirrhotic patients demonstrated an increased manganese content in the brain and more specifically in the pallidum (Figure 2 ; Krieger et al., 1995; Maeda et al., 1997; Pomier-Layrargues et al., 1995) ; in these patients, other causes for MRI pallidal hyperintensities had been ruled out. Further evidence suggesting that MR images result from manganese deposition is provided by observations in patients receiving long term parenteral nutrition where typical pallidal images disappeared after cessation of manganese supplementation (Mirowitz et al., 1991; Mirowitz et al., 1992) . Prolonged inhalation of manganese dusts in miners produces similar MR images (Nelson et al., 1993) ; furthermore exposure of monkeys to manganese administered either by inhalation or intravenously results in selective pallidal hyperintensities on MR imaging (Shinotoh et al., 1995) . 
RELATIONSHIP BETWEEN BRAIN MANGANESE DEPOSITION AND CHRONIC LIVER DISEASE
Average daily oral manganese intake is 2.5 -3mg. Only 1-3% of this normally reaches the systemic circulation because manganese is rapidly cleared by the liver and excreted into the bile (Papavasiliou et al., 1966) . Increases in blood manganese levels have been reported previously in cirrhotic patients (Spahr et al., 1996; Versieck et al., 1974; Hauser et al., 1994; Hauser et al., 1996) and it was shown that blood manganese correlated with brain MRI changes in patients with chronic liver disease ( Figure 3 ).
Potential mechanisms responsible for manganese overload include a decrease in elimination via biliary excretion and an increased systemic availability due to portosystemic shunting.
Cirrhosis is associated with a variable degree of cholestasis that can diminish biliary manganese excretion. In addition, abnormalities of microcirculation (capillarization of the sinusoids and/or intrahepatic shunting) are present in a cirrhotic liver. Alternatively (or additionally) increased blood manganese in cirrhotic patients could result from the presence of portal-systemic collaterals produced either spontaneously or following surgical (portocaval anastomosis) or transjugular intra-hepatic portosystemic shunt (TIPS). Spahr et al., 1996) .
Experimental and clinical observations provide some clues to the relative importance of these potential mechanisms. Portosystemic shunting plays a major role. We previously observed significant correlations between blood manganese, pallidal hyperintensity and the presence of portal-systemic shunting in cirrhotic patients (Spahr et al., 1996) . A significant increase of pallidal hyperintensity has been reported to occur after TIPS (Krieger et al., 1997) . Typical pallidal images were also described in a patient with patent ductus venosus (spontaneous portocaval shunt) in the absence of liver disease (Yanai et al., 1995) and in 6 patients with portal vein thrombosis, portal-systemic collaterals and a normal liver (Nolte et al., 1998) . On the other hand, the important pathogenetic role of liver failure is illustrated by the disappearance of pallidal hyperintensity several months after liver transplantation (Pujol et al., 1993) . More recently, brain manganese accumulation was observed in a rat model of cholestatic cirrhosis as well as in rats with end-to-side portacaval shunt but with a normal liver (Rose et al., 1997) .
RELATIONSHIP BETWEEN BRAIN MANGANESE ACCUMULATION AND NEUROLOGICAL SYMPTOMS IN CIRRHOTIC PATIENTS
Manganese neurotoxicity had previously been reported in miners after a prolonged exposure to manganese dust, resulting in extrapyramidal symptoms resembling Parkinson's disease (Yamada et al., 1986) . In cirrhotic patients a high incidence of extrapyramidal symptoms is observed when a detailed and careful neurological evaluation is performed (Spahr et al., 1996) . Moreover, anatomical or functional lesions in the pallidum might induce cognitive deficits which are part of the clinical spectrum of neurological symptoms associated with hepatic encephalopathy (Iregren, 1994; Mergler and Baldwin, 1997) .
The question then arises as to whether pallidal manganese accumulation in cirrhotic patients might be related to the occurrence of neurological dysfunction in these individuals. Studies attempting to correlate neurological symptoms with MR imaging used as an index of brain manganese content have so far yielded conflicting results (Krieger et al., 1996; Kulisevsky et al., 1992; Spahr et al., 1996; Spahr et al., 1998; Taylor-Robinson et al., 1995; Weissenborn et al., 1995) . This is not surprising because MRI provides only a semi-quantitative estimate of brain manganese concentration. Unfortunately, in vivo measurement of brain manganese is impossible to perform. An interesting alternative to evaluate the pathophysiological significance of brain manganese deposits would be to evaluate the influence of changes in liver function (before and after liver transplantation) or the degree of portosystemic shunting (before and after TIPS) on both neurological status and MR signal intensities. Accordingly it has been demonstrated that, several months after liver transplantation, neurological dysfunction improved or normalised and that MR pallidal hyperintensity disappeared (Devenyi et al., 1994 , Pujol et al., 1993 . More recently, it has been shown that, after the placement of an intrahepatic shunt, pallidal hyperintensity and neurological impairment worsened in a population of cirrhotic patients treated with this procedure compared to a control group (Krieger et al., 1997) .
There are also similarities between the neuropathologic lesions observed in the brains of monkeys and humans intoxicated with manganese (Yamada et al., 1996) and the brains of cirrhotic patients who died with hepatic encephalopathy (Butterworth et al., 1987) ; Alzheimer type II changes have been observed in both circumstances and were predominant present in basal ganglia.
To summarize, increasing evidence supports a pathophysiologic link between brain manganese accumulation and the onset of neurological dysfunction in cirrhotic patients. However, the mechanisms of manganese neurotoxicity are still speculative.
It has been suggested that manganese might influence dopaminergic neurotransmission. Chronic inhalation of manganese in primates results in a 60-80% increase in pallidal manganese and in concomitantly reduced dopamine concentrations (Bird et al., 1984) . Other studies have demonstrated that manganese stimulates dopamine release from nerve endings (Drapeau and Machshev, 1984) and displaces dopamine from its storage sites (Lista et al., 1986) . Chronic manganese administration causes increased activity of the monoaminedegrading enzyme monoamine oxidase (MAO) in brain (Subhash and Padmashree, 1990, Leung et al., 1986) . Increased activities of both MAOA and MAOB isoforms have been described in autopsied brain tissue from cirrhotic patients who died in hepatic coma (Raghavendra Rao et al., 1993) and a selective loss of binding sites for the dopamine D2 receptor ligand 3H spiperone has been observed in pallidum of cirrhotic patients (Bergeron et al., 1989) .
A number of other mechanisms for manganese neurotoxicity have been suggested (Aschner et al., 1991) : alterations of membrane fluidity, interference with enzymatic function in the CNS (such as glutamine synthetase, cytochrome P450-dependent drug hydroxylation activity, calmodulin-related Ca2+-ATPase activity), inhibition of [H3]-kainic acid, a glutamate receptor ligand, to forebrain membranes and the creation of oxidative stress following manganese accumulation within the mitochondria.
CONCLUSIONS AND PERSPECTIVES FOR THE FUTURE
There is evidence to suggest that chronic liver insufficiency and portosystemic shunting results in accumulation of manganese in the brain and particularly in the basal ganglia. The pathophysiological significance of this region-selective manganese deposition remains to be established.
There is a poor relationship between cognitive abnormalities associated with hepatic encephalopathy and brain manganese overload; however the occurrence of extrapyramidal disorders is increasingly recognized in cirrhotic patients and there is a rational basis to hypothesize a relationship between manganese accumulation in basal ganglia and the presence of certain cognitive and motor symptoms. Clearly, further studies are needed to address these issues. If neurotoxic effects of manganese are clearly established in the future, chelation therapy could be tried in the hope of removing manganese and improving neurological dysfunction in patients with chronic liver diseases.
